During the NLS Days 2022, we asked everyone representing InfraLife at the meeting the question: “Why is InfraLife important?” Read their answers below! InfraLife is… Read More »Voices from the InfraLife team at NLS Days 2022
On September 28-29 2022, InfraLife participated at the Nordic Life Science (NLS) Days in Malmö, Sweden, one of the largest meetings for life science industry in the Nordics. This was the first time that these three research infrastructures participated together, and it was a success!
Hanna Barriga has over 10 years of experience engineering and characterizing lipid systems. Her research focuses on understanding how lipid structures impact nanoparticle performance, which includes developing lipid nanoparticles for RNA delivery. We got the opportunity to talk to Hanna to learn how she uses research infrastructure to take her research towards the applied biology of drug targeting.
Development of national research infrastructure is of utmost importance to Sweden’s as a strong life science nation. The InfraLife project gathers Sweden’s large research infrastructures SciLifeLab, MAX IV and ESS. The report Stärkt fokus på framtidens forskningsinfrastruktur (SOU 2021:65) has gone through a referral process and during the government’s life science office´s yearly life science conference one of the sessions posed the question: Research and research infrastructure – Is national access/availability possible? InfraLife’s answer is YES!
Under senaste tid har forskningsinfrastrukturernas roll uppmärksammats och diskuterats flitigt. Betänkandet Stärkt fokus på framtidens forskningsinfrastruktur (SOU 2021:65) har besvarats med remissyttranden och Life Science kontoret har arrangerat årlig life science konferens.
Selma Maric, Esko Oksanen and Michael Hall on the value of taking courses and networking.
Robert Schnell is a scientist at Karolinska Institute focusing on development of novel antibiotic candidates. He has used both SciLifeLab and MAX IV laboratory infrastructures in a multifaceted project addressing the problem of infectious diseases in the context of the silent pandemic of antimicrobial resistance (AMR).